CryoPort (NASDAQ:CYRX) Posts Earnings Results, Beats Expectations By $0.05 EPS

by · The Cerbat Gem

CryoPort (NASDAQ:CYRX – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05, Zacks reports. CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%. CryoPort updated its FY 2025 guidance to EPS.

CryoPort Price Performance

Shares of NASDAQ CYRX traded up $0.18 during trading on Tuesday, hitting $9.22. The company had a trading volume of 1,314,180 shares, compared to its average volume of 569,853. The company has a market cap of $461.62 million, a P/E ratio of 6.93 and a beta of 1.61. CryoPort has a 52 week low of $4.58 and a 52 week high of $11.44. The business’s 50-day moving average is $9.54 and its 200 day moving average is $7.90. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24.

Insider Buying and Selling at CryoPort

In other CryoPort news, Director Robert J. Hariri sold 25,000 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $9.71, for a total value of $242,750.00. Following the transaction, the director owned 51,275 shares of the company’s stock, valued at approximately $497,880.25. This represents a 32.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert Stefanovich sold 9,300 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total value of $80,631.00. Following the completion of the transaction, the chief financial officer directly owned 207,213 shares in the company, valued at $1,796,536.71. This represents a 4.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 39,300 shares of company stock worth $366,381 in the last ninety days. 10.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its holdings in shares of CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after purchasing an additional 4,375 shares during the period. Creative Planning acquired a new position in shares of CryoPort in the second quarter worth $96,000. State of Wyoming raised its holdings in shares of CryoPort by 30.2% during the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after acquiring an additional 3,301 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in CryoPort by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock valued at $136,000 after purchasing an additional 1,557 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new stake in CryoPort during the second quarter valued at $254,000. 92.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CYRX has been the topic of a number of recent analyst reports. BTIG Research lifted their price target on CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a report on Wednesday, October 8th. Leerink Partners raised CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 target price on the stock in a report on Wednesday, August 6th. KeyCorp raised CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 target price on the stock in a report on Wednesday, August 6th. Finally, Leerink Partnrs raised CryoPort from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, CryoPort currently has a consensus rating of “Moderate Buy” and an average price target of $12.56.

Get Our Latest Stock Report on CYRX

About CryoPort

(Get Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Featured Stories